Monoterpenes have been shown to both prevent and treat mammary cancer in animal models and are currently in clinical testing in advanced cancer patients. In this study, we investigated a biochemical modulation associated with the antitumor activity of monoterpenes, the inhibition of protein isoprenylation in monoterpene chemoprevention target tissue, i.e. the in situ mammary gland epithelial cells. We first developed a new methodology that for the first time permitted the study of protein isoprenylation and other products in the mevalonate pathway in in situ mammary cells. Using this approach, we found that chronically feeding rats with an anticancer dose of perillyl alcohol resulted in a 22% inhibition of coenzyme Q synthesis and a 19% inhibition of small G protein isoprenylation in mammary gland epithelial cells in situ. The greatest inhibition of small G protein isoprenylation observed was the 28% inhibition of isoprenylation of RhoA by type I geranylgeranyl protein transferase (GGPTase). Given that some substrates of type I GGPTase, such as RhoA and Rac1, have transforming properties, the possibility that the inhibition of type I GGPTase will change the cellular location and functionality of these proteins and thus contribute to the chemoprevention activity of monoterpenes, is discussed.
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Introduction
Monoterpenes are geranyl pyrophosphate-derived plant products (1) . This class of compounds has the potential to both prevent and treat a variety of cancers including breast cancer (2) (3) (4) (5) . Two monoterpenes, limonene and perillyl alcohol (POH*), are currently in anticancer clinical trials (6, 7) . In order to best use these compounds and to identify or design better agents in this class, it is important to understand the biochemical modulations associated with the preventive and the therapeutic activities of these compounds. One such monoterpene-induced biochemical modulation of interest is the inhibition of protein isoprenylation (8, 9) .
Protein prenylation modifies certain cellular proteins with either a 15-carbon farnesyl or a 20-carbon geranylgeranyl group generated from the mevalonate pathway (reviewed in 10). There are at least three enzymes, farnesyl-protein transferase (FPTase) and type I and type II geranylgeranyl-protein transferases (GGPTases), that catalyze protein prenylation reactions (10) . These enzymes have substrate specificities with regards both to the isoprenylation signal in the form of a short amino acid sequence located at the carboxyl terminal end of the protein substrates, and to the carbon chain length of the lipid substrates, farnesyl pyrophosphate or geranylgeranyl pyrophosphate (10) . As much as 2% of the cellular proteins are isoprenylated in certain cell types, and isoprenylation is important to the functionality of the majority of these proteins (11) (12) (13) . Among these proteins, some perform basic cellular functions directly and some are involved in the signal transduction pathways that regulate cell proliferation, differentiation and death (12, 13) . Several isoprenylated proteins, including Ras (substrate of FPTase), RhoA and Rac1 (both are substrates of type I GGPTase), have been shown to have transforming properties (14) (15) (16) . At least in the case of Ras, isoprenylation is required for its transforming activity (17, 18) , and inhibitors of FPTase have been shown to alter signal transductions (19, 20) , revert the ras-induced transforming phenotype in tissue culture models (21) (22) (23) , and inhibit the growth or cause the regression of ras-related tumors in animal models (24) (25) (26) .
We have shown that monoterpenes inhibit the activity of purified mammalian and yeast FPTase and type I GGPTase (27) . The monoterpene inhibition of these two enzymes were quantitatively equivalent (27) . An analysis of this enzyme inhibition demonstrated that monoterpenes were competitive inhibitors of the isoprene substrates (27) . Monoterpenes and their in vivo metabolites can also inhibit the prenylation of small G proteins in NIH3T3 cells (8, 9) . In contrast to observations with purified enzymes, monoterpenes had greater inhibitory activity for GGPTases than FPTase in intact NIH3T3 cells (28) . Both quantitative and qualitative differences for several FPTase inhibitors have been observed when their effects in vitro and in vivo were evaluated (21, 22, 29) . Furthermore, differences in the inhibitory activity exist when the inhibition of these enzymes by monoterpenes were evaluated in different cell lines (Z.Ren and M.N.Gould, unpublished data). Therefore, in determining the mechanism underlying the anticancer activity of monoterpenes, it is important to evaluate this biochemical effect in both the particular cell type and the in situ setting. Studies of protein prenylation in in situ tissues have been difficult to execute because of methodological limitations. To our knowledge, the only cell type thus far studied for protein prenylation in situ was that of the retina (30) . In that study, Anant et al. injected [ 3 H]mevalonic acid intravitreally and showed that a series of proteins could be prenylated in the cells of the retinas (30) .
In this study, by developing a novel method to quantify protein isoprenylation in situ, we were able to investigate the inhibition of protein isoprenylation by monoterpenes in in situ rat mammary epithelial cells: the primary tumor prevention target of monoterpenes in the rat mammary model. Using the same methodology, we also investigated the effect of monoterpenes on two additional products of the mevalonate pathway, coenzyme Q (CoQ) and cholesterol. These along with protein isoprenylation were shown to be inhibited in cultured mammalian cells in our previous studies (31) . 
Materials and methods

Materials
Animal feeding
All animals used in this study were 2-to 3-month-old inbred female WistarFurth rats from Harlan Sprague-Dawley (Madison, WI). After being acclimated to powdered laboratory animal chow (Teklab laboratory, catalog number 7001, Madison, WI) for several days, the rats were randomly assigned in pairs to either control (base diet) or 2% POH (w/w in base diet) group. Each rat that received the control diet was pair-fed to its counterpart in the POH group. Diets were replaced daily. The animals were put on 2% POH diet for at least 2 weeks before the [ 14 C]mevalonolactone infusions were performed.
Infusion of [ 14 C]mevalonolactone into mammary gland
To minimize non-specific exchange-labeling, 
Isolation of rat mammary epithelial cells
At 3 h (unless described otherwise) after infusion, the successfully infused glands were removed and mammary epithelial cells in the form of ductal fragments were isolated as described by Gould et al. (33) with slight modifications. Briefly, infused mammary glands were removed from female Wistar-Furth rats and finely minced. The minced tissue was digested for 2 h in DMEM that contained 2 mg collagenase/ml medium. DNase was added during the last 10 min of digestion. The tissue was then washed with DMEM supplemented with 10% calf serum, 330 µg/ml glutamine and 54 µg/ml gentamycin and passed through a 53-µm pore-size filter. The trapped fragments containing mostly mammary epithelial cells were pelleted.
Analysis of protein prenylation, CoQ synthesis and cholesterol synthesis
The above collected rat mammary epithelial cells were washed with PBS and lysed with RIPA buffer (PBS, 1% nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 100 µg/ml phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate and 0.15-0.3 TIU/ml aprotinin). Cell debris was pelleted by centrifugation and discarded. The supernatant was collected and protein concentrations were determined by BCA assay. Total protein prenylation was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Isoprenylation of specific small G proteins was also analyzed by SDS-PAGE following immunoprecipitation (28) . Radiolabeled CoQ and cholesterol were analyzed by TLC (31) . Quantitation of radioactivity incorporated into proteins, CoQ and cholesterol was done with a Phosphorimager (Molecular Dynamics, Sunnyvale, CA) and an ImageQuant computer program.
Results
Labeling rat mammary epithelial cells with [ 14 C]mevalonolactone in situ
A method for labeling in situ mammary ductal cells with [ 14 C]mevalonolactone was developed in order to study the 828 effects of dietary POH on protein prenylation, CoQ synthesis and cholesterol synthesis in rat mammary gland epithelial cells in situ. We first evaluated the effect of lovastatin, an HMGCoA reductase inhibitor, on the labeling efficiency of products of the mevalonate-lipid pathway. In rat mammary epithelial cells isolated from the in situ glands that had been infused with 12 µCi of [ 14 C]mevalonolactone per gland, 14 C-labeled small G proteins, CoQ and cholesterol were detectable at 3 h post-infusion ( Figure 1A and B) . The presence of 2.5 mM (10 µg in 10 µl of 0.9% NaCl solution) lovastatin in the infusion solution did not enhance the labeling of proteins, CoQ or cholesterol as it did in cultured cells ( Figure 1A-C) . In fact, lovastatin decreased the labeling of CoQ (P Ͻ 0.05, Student's t-test) and cholesterol (P Ͻ 0.005, Student's t-test). We next investigated the effect of labeling time on the labeling efficiency of the mevalonate pathway. As shown in Figure 2 , at 5% level of significance (Student's t-test), the only differences in labeling efficiency with regards to the labeling time over a 20-h period were the significantly higher CoQ labeling in in situ rat mammary gland epithelial cells labeled for 20 h in comparison with that for 1 h, and the significantly higher cholesterol labeling in in situ rat mammary gland epithelial cells labeled for 3 h, 6 h or 20 h in comparison with that for 1 h. We chose to use the 3-h labeling protocol to maximize the relatively weak labeling of prenylated proteins in the following experiments. This time period is also consistent with the labeling period we used in our previous in vitro studies.
Effects of dietary POH on mevalonate metabolism in mammary epithelium in situ
With the establishment of the method for quantifying protein prenylation, CoQ synthesis and cholesterol synthesis in rat mammary gland epithelial cells in situ, experiments were carried out to investigate the effects of dietary POH on these biochemical processes. Besides the total protein prenylation, the modulation of individual protein prenylation enzymes was studied by immunoprecipitation of representative substrates of FPTase, type I GGPTase and type II GGPTase, Ras, RhoA and Rab6, from [ 14 C]mevalonolactone-labeled in situ rat mammary gland epithelial cells. Figure 3 shows the typical SDS-PAGE and TLC profiles of prenylated proteins and lipids from a representative experiment. The results from several such experiments are summarized in Table I . Small G protein isoprenylation and CoQ synthesis, but not cholesterol synthesis, were inhibited in the mammary parenchyma of animals fed POH. The inhibition of small G protein isoprenylation and CoQ synthesis were both~20%. The 20% inhibition of total small G protein isoprenylation includes a 17% inhibition of Ras prenylation by FPTase (P Ͻ 0.05) and a 28% inhibition of RhoA prenylation by type I GGPTase (P Ͻ 0.01). The 13% inhibition of Rab6 prenylation by type II GGPTase is not statistically significant (P Ͻ 0.05).
Discussion
Monoterpenes such as POH have anticancer activities as both chemoprevention and chemotherapeutic agents (2-5). It has previously been shown that monoterpenes, including POH, competitively inhibited protein prenylation in purified enzyme systems (27) and in NIH3T3 cell culture (8, 9, 28) . In addition, POH also inhibited other aspects of isoprene metabolism including CoQ synthesis and cholesterol synthesis (31) . In order to evaluate these effects of the monoterpenes in the context of their chemopreventive activities, it is important to test POH for its chemopreventive activity in the inhibition of isoprene metabolism in target tissue, such as in mammary glands. In order to test model the metabolism and pharmacokinetics of the inhibitor in vivo and also to study the drug-target tissue in its normal physiological state, we developed a novel method that allowed detailed studies of isoprene metabolism in in situ mammary gland, which is a key target for monoterpene chemoprevention. The development of this method took advantage of the fact that the mammary gland is simple epithelium in which all epithelial cells abut the ductal lumen. This lumen has a small volume (~15 µl/gland), which can be filled with a radiolabeled precursor of the mevalonate pathway such as [ 14 C]mevalonolactone. Such a radiolabeling methodology was used to quantify protein isoprenylation, CoQ and cholesterol syntheses in in situ mammary gland of rats that were chronically fed control or anticancer dose of 2% POH diet.
Levels of 2% of POH in the diet modestly inhibited CoQ synthesis and protein prenylation in in situ mammary cells, but not cholesterol synthesis. Since POH is metabolized very quickly to perillic acid and dihydroperillic acid in rats (34), the actual active compound is likely to be one or both of the metabolites instead of POH itself.
The inhibition of the isoprenylation of small G proteins, although modest, has the potential to mediate at least some of the biological effects of the monoterpenes, such as the inhibition of cell growth. Althoughe Ras isoprenylation was inhibited by 17% in this study, the ability of monoterpenes to inhibit posttranslational modification in cultured cells has been cell line (sub-line) specific (8, 28 , Z.Ren and M.N.Gould, unpublished data). Furthermore, in an NMU-induced rat mammary tumor preventive study, dietary monoterpenes reduced the average number of tumors per rat by 50% but did not alter the percentage of tumors with activated ras (35) . These previous data, together with data presented here, suggest that while monoterpene treatment can modestly inhibit Ras farnesylation in in situ mammary gland epithelial cells, this biochemical inhibition does not underlie the prevention of mammary cancer by monoterpenes. (GGPTase I) 28 Ϯ 6 (P Ͻ 0.01, n ϭ 4) Rab6 prenylation (GGPTase II) 13 Ϯ 9 (not significant, n ϭ 4) CoQ synthesis 22 Ϯ 6 (P Ͻ 0.05, n ϭ 5) Cholesterol synthesis 0 Ϯ 12 (not significant, n ϭ 5) a Mean percentage of inhibition Ϯ SEM. Test of significance was performed using Student's t-test; n is the number of independent experiments (10 to 14 animals were used in each experiment).
The most consistent inhibition of protein prenylation by the monoterpenes in the various in vitro, in vivo and in situ models is the inhibition of proteins prenylated by type I GGPTase (27, 28) . Two substrates for this enzyme, Rac1 (15) and RhoA (16) , have been shown to have transforming potential in cultured cells. In addition, these and other type I GGPTase substrates play important roles in both cell signaling and cell structure (12, 13, 36, 37) . Whether the inhibition of their prenylation could in turn modulate their cellular localization and hence their functionality in in situ rat mammary gland epithelial cells is currently under investigation in our laboratory. The long-term goal of testing whether there is linkage between this in situ biochemical effect and the tumor preventive effect of the monoterpenes will be facilitated by the development of specific inhibitors of type I GGPTases, and the evaluation of their anticancer properties at a dose that inhibits protein isoprenylation to a similar level as does dietary POH.
The inhibition of CoQ synthesis may also be mechanistically involved in the monoterpenes anticancer activities. CoQ is a component of the electron transfer chain in mitochondria that generates ATP. Depletion of ATP has been proposed to contribute to the anticancer mechanisms of several drugs (38) (39) (40) (41) (42) (43) (44) . CoQ is also a component of the trans-cytoplasm membrane 830 electron transfer chain (45) , which stimulates cell growth (46) , activates the phosphorylation of membrane proteins (47) and induces the expression of c-myc and c-fos proto-oncogenes (48) . The inhibition of CoQ synthesis may attenuate the signals sent by this electron transport system and may modulate the expression of some genes such as c-myc and c-fos and hence inhibit cell growth. Another major cellular function of CoQ is its role as a strong antioxidant in its reduced form (49) (50) (51) (52) . The inhibition of CoQ synthesis may make cells more vulnerable to free radical damages. This is especially true for tumor cells since they usually contain lower levels of enzymes to deal with oxygen radicals and hydrogen peroxide (53) (54) (55) . CoQ synthesis was inhibited by 22% in rat mammary gland epithelial cells that had received 2% dietary POH. Whether such a modest inhibition can mechanistically participate in the prevention activities of the monoterpenes requires further investigation.
We have previously proposed that prevention at the promotion/progression stage and the therapy of advanced malignancies by monoterpenes may mechanistically share common molecular targets (56) . Thus, the results from this study may also help to explain the mechanism by which monoterpenes may act as chemotherapy agents.
